Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Galapagos Islands -- Ignore unavailable to you. Want to Upgrade?

To: Jorj X Mckie who wrote (22324)	1/21/2003 12:22:31 PM
From: Rainy_Day_Woman	Read Replies (1) \| Respond to of 57110

position is everything :) [full house]

To: Jorj X Mckie who wrote (22324)	1/21/2003 12:43:06 PM
From: tuck	Read Replies (1) \| Respond to of 57110

Jorj, Most everything that can be shorted has a fair degree of news risk. I think IDBE is still a good candidate, getting ahead of itself. Wondering if the blitz is to get a good price for an offering. ALKS, but Risperdal Conta will probably be approved eventually. Good regulatory news could really hurt, otherwise it looks vulnerable. A watchful eye and tight stops suggested on all these. Had you asked me last week, I would have said AGIX, but they just gotten beaten up today for announcing an offering. AGEN is starting to pay the price for the same move (I am short from $11 there via sold calls; waiting for time premium to erode with a fair degree of comfort). Both may have some downside left, but have already moved significantly. CEPH priced for perfection, IMO. If you are expecting a bounce, and CHIR gets to $41, I would dare to short it into earnings late this month (29th I think, but double check my fallible memory). I'd feel safer shorting it after earnings. VXGN if you can get shares, but it's on that UPC11830 (I think that's the code; the one that says shares are hard to come by), and the options are expensive. I am short via naked calls. One could argue that the good news has been priced into AMGN, and that it will move according to sector favoritism for a while. Of all these, I think IDBE has the most downside in it, and I would consider it my best idea, but it seems to be a bit of darling right now. I'll be curious to hear your thoughts, as always. Cheers, Tuck